Treatment of chronic hepatitis B in children with recombinant alfa interferon. Different response according to age at infection

J Clin Gastroenterol. 1993 Dec;17(4):296-9. doi: 10.1097/00004836-199312000-00006.

Abstract

The objective of this study was to investigate the possibility of predictive factors of response to treatment with interferon in children with chronic hepatitis B virus infection. We analyzed the influence on the response rate of age, sex, mode of acquisition of infection, severity, and duration of disease in 16 children with chronic hepatitis B treated with 3 MU of recombinant alpha-interferon 2b three times a week for 6 months. Six months after the end of treatment, eight patients (50%) had cleared HBV DNA, seroconverted to anti-HBe and normalized serum transaminase values. Response was significantly higher in those whose serum transaminase levels were > 100 IU/liter before treatment (70%) and those infected after birth (72%) compared with those with lower serum transaminase levels (16%) and those infected at birth (7%). Our findings indicate that a 6 month course of low dose interferon (3 MU) is highly effective in children with horizontally transmitted chronic hepatitis B virus infection, but noneffective in children infected at birth.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Age Factors
  • Child
  • Child, Preschool
  • Female
  • Hepatitis B / immunology
  • Hepatitis B / therapy*
  • Hepatitis, Chronic / immunology
  • Hepatitis, Chronic / therapy*
  • Humans
  • Interferon Type I / administration & dosage
  • Interferon Type I / therapeutic use*
  • Male
  • Recombinant Proteins

Substances

  • Interferon Type I
  • Recombinant Proteins